Page last updated: 2024-08-21

adamantane and Familial Nonmedullary Thyroid Cancer

adamantane has been researched along with Familial Nonmedullary Thyroid Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Dong, W; He, L; Qin, Y; Sun, W; Wang, Z; Zhang, H; Zhang, T	1

Other Studies

1 other study(ies) available for adamantane and Familial Nonmedullary Thyroid Cancer

Article	Year
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway. Medical oncology (Northwood, London, England), 2020, Oct-01, Volume: 37, Issue:11 Topics: Adamantane; Animals; Cell Line, Tumor; Cell Movement; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Matrix Metalloproteinase 2; Mice; Neoplasm Invasiveness; NF-E2-Related Factor 2; Promoter Regions, Genetic; Signal Transduction; Thyroid Cancer, Papillary; Vascular Endothelial Growth Factor A	2020

Article

Year

The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.

Medical oncology (Northwood, London, England), 2020, Oct-01, Volume: 37, Issue:11

Topics: Adamantane; Animals; Cell Line, Tumor; Cell Movement; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Matrix Metalloproteinase 2; Mice; Neoplasm Invasiveness; NF-E2-Related Factor 2; Promoter Regions, Genetic; Signal Transduction; Thyroid Cancer, Papillary; Vascular Endothelial Growth Factor A

2020